Eris Lifesciences Limited
Simbols: ERIS.NS
NSE
843.7
INRTirgus cena šodien
29.8535
P/E koeficients
2.0937
PEG koeficients
114.78B
MRK Cap
- 0.00%
DIV ienesīgums
Eris Lifesciences Limited (ERIS-NS) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 892.4 | 1772.4 | 522.7 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 332.2 | 1264.5 | 154 | |||||||||||
balance-sheet.row.net-receivables | 0 | 2966.9 | 2260.9 | 2280.6 | |||||||||||
balance-sheet.row.inventory | 0 | 1314.3 | 1179.1 | 944.7 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 2473.5 | 1060.8 | 922.5 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 7647.2 | 6273.3 | 4670.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 3773.8 | 1918.6 | 778.8 | |||||||||||
balance-sheet.row.goodwill | 0 | 3318.5 | 934.7 | 934.7 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 18806 | 6596 | 6840.8 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 22124.5 | 7530.7 | 7775.5 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 68.8 | 4208.4 | 2859.2 | |||||||||||
balance-sheet.row.tax-assets | 0 | 2739.4 | 2431.3 | 2006.3 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 319.6 | 359 | 257.6 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 29026.1 | 16448.1 | 13677.3 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 36673.3 | 22721.4 | 18347.8 | |||||||||||
balance-sheet.row.account-payables | 0 | 1247.7 | 1177.7 | 1026.2 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 1932.9 | 40.1 | 23.3 | |||||||||||
balance-sheet.row.tax-payables | 0 | 39 | 70 | 77.5 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 6834.2 | 803.9 | 44.5 | |||||||||||
Deferred Revenue Non Current | 0 | 87.4 | 56.9 | 61.1 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 217.2 | 152.4 | 132.5 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 10034.2 | 1642.9 | 914.3 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 466.9 | 394 | 67.7 | |||||||||||
balance-sheet.row.total-liab | 0 | 14466.5 | 3639.4 | 2583.6 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 21930.1 | 19062.4 | 15722.7 | |||||||||||
balance-sheet.row.common-stock | 0 | 136 | 135.9 | 135.8 | |||||||||||
balance-sheet.row.retained-earnings | 0 | 21559.3 | 18736.5 | 15503.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 29.8 | 20.7 | 41.5 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | -21695.3 | -18872.5 | -15638.9 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 21959.9 | 19083.1 | 15764.2 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 36673.3 | 22721.4 | 18347.8 | |||||||||||
balance-sheet.row.minority-interest | 0 | 246.9 | -1.1 | 0 | |||||||||||
balance-sheet.row.total-equity | 0 | 22206.8 | 19082 | 15764.2 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 143.5 | 4208.4 | 2436.4 | |||||||||||
balance-sheet.row.total-debt | 0 | 8767.1 | 844.1 | 67.8 | |||||||||||
balance-sheet.row.net-debt | 0 | 8206.9 | 336.1 | -300.9 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 4046.4 | 4422 | 3945 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 1170.9 | 647 | 429.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | -809.7 | -976.6 | -670.9 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 31.2 | 13.6 | 11.2 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | -1755.4 | -299 | 53.3 | |||||||||||
cash-flows.row.account-receivables | 0 | -1171.4 | -204.8 | 159 | |||||||||||
cash-flows.row.inventory | 0 | 47.4 | -234.4 | -249.9 | |||||||||||
cash-flows.row.account-payables | 0 | -105 | 151.6 | 25.7 | |||||||||||
cash-flows.row.other-working-capital | 0 | -526.5 | -11.3 | 118.6 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 233.9 | -24.4 | -14.7 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -8414.2 | -1210.3 | -257.6 | |||||||||||
cash-flows.row.acquisitions-net | 0 | -6554.9 | -103 | -2.8 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -300 | -2677.7 | -3733.9 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 5204.4 | 795.9 | 774.2 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 243.7 | -1 | -13.4 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -9821 | -3196.1 | -3233.6 | |||||||||||
cash-flows.row.debt-repayment | 0 | -3500 | -450 | -0.1 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 22.8 | 67.5 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 3477.2 | -450 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | -999.1 | -816.2 | -746.8 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 7879.4 | 1201.8 | -77.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 6880.3 | -447 | -824 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 74.9 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 51.5 | 139.6 | -303.9 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 560.2 | 508.7 | 369.1 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 508.7 | 369.1 | 673.1 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 2917.4 | 3782.6 | 3753.6 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -8414.2 | -1210.3 | -257.6 | |||||||||||
cash-flows.row.free-cash-flow | 0 | -5496.8 | 2572.3 | 3496 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 16618.2 | 13261.7 | 11926.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 0 | 3523.5 | 2608.1 | 2418.7 | |||||||||||
income-statement-row.row.gross-profit | 0 | 13094.7 | 10653.6 | 9507.8 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 111.5 | 10.4 | 4.5 | |||||||||||
income-statement-row.row.operating-expenses | 0 | 8898.1 | 6403 | 5620 | |||||||||||
income-statement-row.row.cost-and-expenses | 0 | 12421.6 | 9011.1 | 8038.7 | |||||||||||
income-statement-row.row.interest-income | 0 | 23 | 61 | 22.9 | |||||||||||
income-statement-row.row.interest-expense | 0 | 261.7 | 41.5 | 18 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -170.2 | 176.9 | 68.9 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 111.5 | 10.4 | 4.5 | |||||||||||
income-statement-row.row.total-operating-expenses | 0 | -170.2 | 176.9 | 68.9 | |||||||||||
income-statement-row.row.interest-expense | 0 | 261.7 | 41.5 | 18 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1170.9 | 647 | 429.9 | |||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 0 | 4216.6 | 4245 | 3876.1 | |||||||||||
income-statement-row.row.income-before-tax | 0 | 4046.4 | 4422 | 3945 | |||||||||||
income-statement-row.row.income-tax-expense | 0 | 304.8 | 364.1 | 393.6 | |||||||||||
income-statement-row.row.net-income | 0 | 3821.6 | 4061.1 | 3551.3 |
Biežāk uzdotie jautājumi
Kas ir Eris Lifesciences Limited (ERIS.NS) kopējie aktīvi?
Eris Lifesciences Limited (ERIS.NS) kopējie aktīvi ir 36673280000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.818.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 19.153.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.210.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.266.
Kāda ir Eris Lifesciences Limited (ERIS.NS) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 3821580000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 8767110000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 8898080000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.